|
ATRIA
Anticoagulation and Risk factors In Atrial fibrillation
Ongoing trial
 |
Author(s) |
Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE
|
 |
Title(s) |
Prevalence of diagnosed atrial fibrillation in adults
|
|
Reference(s) |
JAMA 2001;285:2370-5 |
|
Disease |
Atrial fibrillation
|
|
Purpose |
To estimate prevalence of atrial fibrillation and US national projections of the numbers of persons with atrial fibrillation through the year 2050
|
|
Study design |
Observational, retrospective
|
|
Follow-up |
18-month period of database data
|
|
Patients |
17,974 adults, aged ≥ 20 years, with non-transient atrial fibrillation diagnosed during the period July 1996 - December 1997
|
|
Treatment regimen |
Observational |
|
Results |
The overall prevalence of atrial fibrillation was 0.95%. Prevalence ranged from 0.1% in adults aged < 55 years to 9.0% in those aged ≥ 80 years. Prevalence was greater in men than in women (1.1% vs 0.8%; p < 0.001). Prevalence was greater in whites than in blacks aged ≥ 50 years (2.2% vs 1.5%; p < 0.001). It was estimated that there are nearly 2.3 million US adults with atrial fibrillation. This was projected to rise to more than 5.6 million by the year 2050, with 88% aged ≥ 65 years and 53% ≥ 80 years. About half will be women
|
|
Comments |
This study has been the basis for a number of publications. A selection of references:
Factor V Leiden polymorphism
– Go AS et al, J Thromb Thrombolysis 2003;15:41–6
Gender differences and target anticoagulation
– Fang MC et al, Circulation 2005;112:1687–91
Kidney disease and risk of thromboembolism
– Go AS et al, Circulation 2009;119:1363–9
Risk stratification
– Fang MC et al, J Am Coll Cardiol 2008;51:810–5 |
|
|
|
